Skip to content

Carbidopa

Carbidopa is a decarboxylase inhibitor used with levodopa. It prevents much of levodopa from being broken down before it reaches the brain, allowing more levodopa to be converted to dopamine where movement symptoms arise.

Sinemet

Parkinson's Disease, Parkinsonism

100mg + 10mg · 100mg + 25mg · 250mg + 25mg

Indicated to address motor coordination deficits to manage parkinsonian tremors and alleviate muscular rigidity.

From$1.05/ tabletView

Stalevo

Parkinson's Disease

200mg + 100mg + 25mg

Designed to support dopamine pathways to manage parkinsonian motor deficits and alleviate muscle stiffness.

From$0.85/ tabletView

Key points

  • Carbidopa is not represented as a standalone medicine in this catalogue.
  • Sinemet contains carbidopa and levodopa.
  • Stalevo contains carbidopa, levodopa and entacapone.
  • Sudden interruption of carbidopa-levodopa can cause a serious withdrawal syndrome.

Sinemet establishes the core pair

Sinemet represents three recorded carbidopa-levodopa strength pairs. It connects with Parkinson’s disease and parkinsonism in the neurology category.

Levodopa crosses into the brain and is converted to dopamine. Carbidopa stays largely outside the brain and limits peripheral levodopa breakdown, which also reduces nausea and vomiting linked to that peripheral conversion.

Stalevo adds entacapone

Stalevo records a three-ingredient tablet: levodopa, carbidopa and entacapone. Entacapone inhibits a different enzyme involved in levodopa metabolism. This third ingredient is the defining distinction from Sinemet, even though both products share the same neurological taxonomy.

Official medicine information warns against suddenly stopping the levodopa-carbidopa combination. Fever, rigid muscles, unusual movements and confusion can follow abrupt interruption. Movement changes, involuntary movements, sleepiness and behavioural effects also belong to the medicine-specific review.

Further reading